Moreover, PUFAs activate PPARα, leading to increased FA β-oxidation; hence, they can shift the energy balance from storage to consumption [41, 43].  n-3 PUFAs have also been proved as safe and efficacious for patients with NAFLD associated with hyperlipidemia, as indicated by reduced hepatic damage and serum lipid levels [44]. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.